Description of Covered Data and Data Collection Activities Clause Samples

Description of Covered Data and Data Collection Activities. Members of the Study Team will visit the Site and participating schools during one week in Winter/Spring 2020. The target week for the Site is scheduled as March 24th to 26th, 2020. The Site agrees to the data collection activities listed below. Winter/Spring 2020:  SFA Director Survey: The SFA Director will respond to questions that will provide information needed to characterize district policies, the school environment, and food service operations.
View SourceView Similar (2)

Related to Description of Covered Data and Data Collection Activities

  • Data Use Each party may use Connected Account Data in accordance with this Agreement and the consent (if any) each obtains from each Connected Account. This consent includes, as to Stripe, consent it receives via the Connected Account Agreement.

  • Procurement of Recovered Materials In the performance of this contract, the Contractor shall make maximum use of products containing recovered materials that are EPA-designated items unless the product cannot be acquired

  • Contract Database Metadata Elements Title: Sayville Union Free School District and Sayville Union Free School Custodial and Maintenance Employees Unit, United Public Service Employees Union (UPSEU), Local 424 (2011) Employer Name: Sayville Union Free School District Union: Sayville Union Free School Custodial and Maintenance Employees Unit, United Public Service Employees Union (UPSEU) Local: 424 Effective Date: 07/01/2011 Expiration Date: 06/30/2015 PERB ID Number: 6131 Unit Size: 55 Number of Pages: 24 For additional research information and assistance, please visit the Research page of the Catherwood website - ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇▇▇▇▇.▇▇▇/library/research/ For additional information on the ILR School - ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇▇▇▇▇.▇▇▇/ 55 People TABLE OF CONTENTS ARTICLE Page XXII ANNUAL LEAVE DAYS 14 XXV BREAKS 18 XXVI CIVIL SERVICE LAW ARTICLE SECTION 75 18 XXVIII DURATION 19 XIV EMERGENCY WORK 11 XXI FOUL WEATHER CLOTHING 14 XI GRIEVANCE PROCEDURE 9 XVI HIGHER JOB CLASSIFICATION 12 XVIII HOLIDAYS 13 XV HOLIDAY AND WEEKEND BUILDING CHECKS 12 V INSURANCE 4 X LAYOFF, DISPLACEMENT AND RECALL ORDER 8 VII MANAGEMENT RIGHTS 7 XXVII MISCELLANEOUS 19 XVII NOTICES OF PROMOTIONS 13 XIII OVERTIME 10 II PAYROLL DEDUCTIONS 1 III PERSONNEL FILES 2 XXIV PHYSICAL EXAMINATIONS 18 XXIII RETIREMENT 16 IX STRIKES AND LOCKOUTS 7 XIX VACATIONS 13 XX VISITATION 14 IV WAGES 3 VI WORKERS' COMPENSATION 6 XII WORKWEEK 10 VIII WRITTEN BOARD POLICY 8 APPENDIX A 20 4/20/2016 AGREEMENT made and entered into this day of November 2013 between the SAYVILLE UNION FREE SCHOOL DISTRICT (hereinafter referred to as the “District”) and United Public Service Employees Union, ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, N.Y. 11779 (hereinafter referred to as the “Union”).

  • Exceptional Access to Thick Registration Data In case of a registrar failure, deaccreditation, court order, etc. that prompts the temporary or definitive transfer of its domain names to another registrar, at the request of ICANN, Registry Operator will provide ICANN with up-­‐to-­‐date data for the domain names of the losing registrar. The data will be provided in the format specified in Specification 2 for Data Escrow. The file will only contain data related to the domain names of the losing registrar. Registry Operator will provide the data as soon as commercially practicable, but in no event later than five (5) calendar days following ICANN’s request. Unless otherwise agreed by Registry Operator and ICANN, the file will be made available for download by ICANN in the same manner as the data specified in Section 3.1 of this Specification.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.